PHATHOM PHARMACEUTICALS, INC. (PHAT) Operating income 2018–2025
PHATHOM PHARMACEUTICALS, INC. (PHAT) annual operating income history from SEC filings — each fiscal year as reported.
-$160.0MFY2025 · since FY2018: -$1.2M → -$160.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$160.0M | +42.3% |
| FY2024 | -$277.5M | -65.8% |
| FY2023 | -$167.3M | +3.0% |
| FY2022 | -$172.4M | -27.7% |
| FY2021 | -$135.1M | -7.5% |
| FY2020 | -$125.7M | -18.3% |
| FY2019 | -$106.2M | -8570.6% |
| FY2018 | -$1.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PHAT financial trends
PHAT RevenuePHAT Net incomePHAT Net marginPHAT Gross profitPHAT Gross marginPHAT Operating marginPHAT Operating cash flowPHAT Free cash flowPHAT Capital expendituresPHAT Return on equityPHAT Stock buybacksPHAT Dividends paidPHAT Total assetsPHAT Total liabilitiesPHAT Shareholders’ equityPHAT overview →